The CEO of CRISPR Therapeutics, Samarth Kulkarni, disclosed in a regulatory filing that he had sold 25,000 shares of company stock at $50.67 per share on April 25, for a total transaction amount of $1,266,638.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Surges 16% as Cantor Fitzgerald Assigns $72 PT
- CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Cantor starts Crispr Therapeutics at Overweight on commercialization chances
- Crispr Therapeutics initiated with an Overweight at Cantor Fitzgerald